Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
暂无分享,去创建一个
Y. Barenholz | A. Gabizon | F. Martin | B. Uziely | B. Kaufman | R. Cohen | R. Catane | T. Safra | A Gabizon | Y Barenholz | B Uziely | T Safra | F. Martín | A. Huang | B Kaufman | R Catane | R Cohen | F Martin | A Huang | B. Kaufman
[1] B. Samuels,et al. Continuous venous infusion of doxorubicin in advanced sarcomas. , 1987, Cancer treatment reports.
[2] Y. Barenholz,et al. Preclinical and Clinical Experience with a Doxorubicin-Liposome Preparation , 1990 .
[3] E. Newlands,et al. Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. , 1979, British Journal of Cancer.
[4] A. Gabizon,et al. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.
[5] J. Lokich,et al. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. , 1984, Annals of internal medicine.
[6] V. Ferrans,et al. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. , 1990, Journal of the National Cancer Institute.
[7] N. Petrelli,et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). , 1993, Cancer research.
[8] F. Martin,et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid , 1992, International journal of cancer.
[9] Y. Barenholz,et al. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. , 1989, Biochimica et biophysica acta.
[10] C. Presant,et al. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] A. Gabizon,et al. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.
[12] G. Hortobagyi,et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma , 1989, Cancer.
[13] L. Benet,et al. Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.
[14] J. Jenkins,et al. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. , 1983, Cancer research.
[15] Y. Barenholz,et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. , 1991, British Journal of Cancer.
[16] M. Woodle,et al. Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.
[17] T. Allen,et al. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.
[18] J J DiStefano,et al. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.
[19] D. Friend,et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.
[20] A. Gabizon,et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. Gabizon. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.
[22] A. Gabizon,et al. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[23] N. Bachur,et al. Adriamycin metabolism in man. Evidence from urinary metabolites. , 1976, Drug metabolism and disposition: the biological fate of chemicals.
[24] B. Hoogstraten,et al. Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.
[25] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[26] M. Bally,et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.
[27] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[28] D. Lasič,et al. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes , 1992, International journal of cancer.
[29] W. Alvord,et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Y. Barenholz,et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. , 1989, European journal of cancer & clinical oncology.
[31] S. Kojima,et al. Increased delivery of gallium-67 to tumors using serum-stable liposomes. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.